Ocular Therapeutix's last-minute gambit fails to salvage its second FDA application, shares plunge
An 11th hour bid by Ocular Therapeutix to salvage its FDA application for their drug/device eye treatment Dextenza got shot down in a hurry on Tuesday.
A year after Ocular received its first rejection of the eye therapy based on manufacturing issues, the Bedford, MA-based company was handed its second complete response letter after inspectors flagged issues during a pre-NDA inspection a couple of months ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.